Literature DB >> 33130519

Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies.

Praveen Mathews Varghese1, Anthony G Tsolaki2, Hadida Yasmin3, Abhishek Shastri4, Janez Ferluga2, Manu Vatish5, Taruna Madan6, Uday Kishore7.   

Abstract

The current coronavirus pandemic, COVID-19, is the third outbreak of disease caused by the coronavirus family, after Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. It is an acute infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This severe disease is characterised by acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and multiple organ dysfunction syndromes. Currently, no drugs or vaccines exist against the disease and the only course of treatment is symptom management involving mechanical ventilation, immune suppressants, and repurposed drugs. The severe form of the disease has a relatively high mortality rate. The last six months have seen an explosion of information related to the host receptors, virus transmission, virus structure-function relationships, pathophysiology, co-morbidities, immune response, treatment and the most promising vaccines. This review takes a critically comprehensive look at various aspects of the host-pathogen interaction in COVID-19. We examine the genomic aspects of SARS-CoV-2, modulation of innate and adaptive immunity, complement-triggered microangiopathy, and host transmission modalities. We also examine its pathophysiological impact during pregnancy, in addition to emphasizing various gaps in our knowledge. The lessons learnt from various clinical trials involving repurposed drugs have been summarised. We also highlight the rationale and likely success of the most promising vaccine candidates.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Anti-virals; COVID-19; Co-morbidities; Life-cycle; Pathophysiology; Pregnancy; SARS-CoV-2; Vaccine

Mesh:

Substances:

Year:  2020        PMID: 33130519      PMCID: PMC7434692          DOI: 10.1016/j.imbio.2020.152008

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  20 in total

1.  Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody.

Authors:  Giovanna Moscato; Paola Mazzetti; Ersilia Lucenteforte; Alfredo Rosellini; Alice Cara; Paola Quaranta; Valerio Mainardi; Pietro Villa; Daniele Focosi; Maria Lanza; Irene Bianco; Alessandro Mazzoni; Marco Falcone; Francesco Menichetti; Fabrizio Maggi; Michele Lai; Giulia Freer; Mauro Pistello
Journal:  J Clin Virol Plus       Date:  2021-05-04

2.  Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.

Authors:  Miao-Hsi Hsieh; Nazar Beirag; Valarmathy Murugaiah; Yu-Chi Chou; Wen-Shuo Kuo; Hui-Fang Kao; Taruna Madan; Uday Kishore; Jiu-Yao Wang
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 3.  Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings.

Authors:  Ish K Midha; Nilesh Kumar; Amit Kumar; Taruna Madan
Journal:  Rev Med Virol       Date:  2020-12-31       Impact factor: 11.043

Review 4.  Microarray patches enable the development of skin-targeted vaccines against COVID-19.

Authors:  Emrullah Korkmaz; Stephen C Balmert; Tina L Sumpter; Cara Donahue Carey; Geza Erdos; Louis D Falo
Journal:  Adv Drug Deliv Rev       Date:  2021-02-02       Impact factor: 17.873

Review 5.  One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages.

Authors:  Fernando González-Candelas; Marie-Anne Shaw; Tung Phan; Urmila Kulkarni-Kale; Dimitrios Paraskevis; Fabio Luciani; Hirokazu Kimura; Manuela Sironi
Journal:  Infect Genet Evol       Date:  2021-04-26       Impact factor: 4.393

6.  In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein.

Authors:  Nabarun Chandra Das; Pritha Chakraborty; Jagadeesh Bayry; Suprabhat Mukherjee
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

Review 7.  COVID-19 and novel mRNA vaccines in pregnancy: an updated literature review.

Authors:  E Joubert; A C Kekeh; C N Amin
Journal:  BJOG       Date:  2021-11-01       Impact factor: 7.331

Review 8.  Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19.

Authors:  Le-le Ma; Hui-Min Liu; Xue-Mei Liu; Xiao-Yu Yuan; Chao Xu; Fang Wang; Jun-Zhi Lin; Run-Chun Xu; Ding-Kun Zhang
Journal:  Eur J Med Chem       Date:  2021-10-04       Impact factor: 6.514

9.  Comparison of pure tone audiometry thresholds and transient evoked otoacoustic emissions (TEOAE) of patients with and without Covid-19 pneumonia.

Authors:  Erkan Yıldız
Journal:  Am J Otolaryngol       Date:  2022-01-29       Impact factor: 1.808

Review 10.  Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease.

Authors:  Nicole Ng; Charles A Powell
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.